Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04332666
Recruitment Status : Not yet recruiting
First Posted : April 3, 2020
Last Update Posted : August 2, 2021
Sponsor:
Collaborator:
Fonds Erasme pour la Recherche Médicale
Information provided by (Responsible Party):
Erasme University Hospital

Tracking Information
First Submitted Date  ICMJE March 27, 2020
First Posted Date  ICMJE April 3, 2020
Last Update Posted Date August 2, 2021
Estimated Study Start Date  ICMJE December 30, 2021
Estimated Primary Completion Date December 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 2, 2020)
ventilator free days [ Time Frame: 28 days ]
composite outcome of mortality and necessity of mechanical ventilation
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 2, 2020)
  • ICU free days [ Time Frame: trough study completion, on average 40 days ]
    number of days free from intensive care unit
  • Hospital length of stay [ Time Frame: through study completion, on average 60 days ]
    Hospital length of stay
  • Time to wean from mechanical ventilation [ Time Frame: through study completion, on average 14 days ]
    Time to wean from mechanical ventilation
  • PaO2/FiO2 changes during drug administration [ Time Frame: 48 hours ]
    PaO2/FiO2 changes during drug administration
  • Deep vein thrombosis incidence [ Time Frame: through study completion, on average 30 days ]
    US confirmed deep vein thrombosis
  • Changes in inflammatory markers [ Time Frame: at randomization, 48 hours after randomization and 72 hours after randomization ]
    including IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, TNF-alpha, interferon gamma
  • RAS effectors levels [ Time Frame: at randomization, 48 hours after randomization and 72 hours after randomization ]
    Ang II and Ang-(1-7) plasmatic levels
  • Radiological findings [ Time Frame: through study completion, on average 30 days ]
    Chest x-ray or CT scan changes
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: April 2, 2020)
Rate of serious adverse events [ Time Frame: study drug administration/day 28 or ICU discharge or death ]
phase 2b = principal safety outcome; phase 3 = secondary outcome
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial
Official Title  ICMJE Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial
Brief Summary

Background: A novel Coronavirus (SARS-CoV-2) described in late 2019 in Wuhan, China, has led to a pandemic and to a specific coronavirus-related disease (COVID-19), which is mainly characterized by a respiratory involvement. While researching for a vaccine has been started, effective therapeutic solutions are urgently needed to face this threaten. The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host 's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that is downregulated in COVID-19 patient and it may potentially improve respiratory function in this setting.

Methods/Design: The Investigators describe herein the methodology of a randomized, controlled, adaptive Phase II/Phase III trial to test the safety, efficacy and clinical impact of the infusion of angiotensin-(1-7) in COVID-19 patients with respiratory failure requiring mechanical ventilation. A first phase of the study, including a limited number of patients (n=20), will serve to confirm the safety of the study drug, by observing the number of the severe adverse events. In a second phase, the enrollment will continue to investigate the primary endpoint of the study (i.e. number of days where the patient is alive and not on mechanical ventilation up to day 28) to evaluate the efficacy and the clinical impact of this drug. Secondary outcomes will include the hospital length of stay, ICU length of stay, ICU and hospital mortality, time to weaning from mechanical ventilation, reintubation rate, secondary infections, needs for vasopressors, PaO2/FiO2 changes, incidence of deep vein thrombosis, changes in inflammatory markers, angiotensins plasmatic levels and changes in radiological findings. The estimated sample size to demonstrate a reduction in the primary outcome from a median of 14 to 11 days is 56 patients, 60 including a dropout rate of 3% (i.e. 30 per group), but a preplanned recalculation of the study sample size is previewed after the enrollment of 30 patients.

Expected outcomes/Discussion: This controlled trial will assess the efficacy, safety and clinical impact of the Angiotensin-(1-7) infusion in a cohort of COVID-19 patients requiring mechanical ventilation. The results of this trial may provide useful information for the management of this disease.

Detailed Description

Rationale for the study The cellular entry of the SARS-CoV-2 can result in a functional reduction of ACE2 activity and this could lead to an increased activity of the Ang II/AT1 axis and decreased levels Ang-(1-7)/MasR expression that could contribute to the severity of the disease. The administration of Ang-(1-7) could reestablish this equilibrium, contributing to decrease pulmonary inflammation e thus decreasing the symptoms of the disease.

Eligible patients and the next of kin (whenever possible) should be informed about the rationale and the aims of the study and potential risks of drug infusion. Local ethical regulations should be otherwise followed. Due to the eligibility criteria and the urgency setting, a delayed written consent may be obtained after randomization from the next of kin and/or the patient (i.e. after ICU discharge).

Randomization will be performed using sealed envelopes with a ratio of 1:1 including information on treatment assignment and a five-digit number, which will be open by the person responsible for drug constitution. Each vial or syringe will be then labeled with the randomly allocated number it will be assigned to the nursing personnel. The doctors and nurses administering the drugs, as well as the local investigators and research personnel who collected data, were unaware of the treatment assignments. Randomization should occur within 24 hours since orotracheal intubation and drug infusion initiated within 4 hours from randomization.

Trial will be conducted in adherence to the current Helsinki Declaration and the standard of good clinical practice. Screening of patients will only start after approval of the ethical committees (EC) in the trial sites. No deviation of the protocol will be implemented without the prior review and approval of the ECs.

Study Treatment Ang-(1-7) is a pre-constitute intravenous lyophilized formulation containing 0.5 mg/ ampoule and will be administered to patients via a dedicated central venous line at the initial dose of 0.1 mcg/Kg/h (equivalent to 2.5 mcg/Kg/day). After the first hour of infusion, if no decrease in mean arterial pressure (decrease superior to 30% or need to increase vasopressors ≥ 50% of an initial dosage to maintain a MAP ≥ 65mmHg), the infusion rate will be increased to 0.2 mcg/Kg/h (equivalent to 5 mcg/Kg/day). The infusion will be continued for up to 48 hours and then stopped. To this end, the substance solution, prepackaged, will be diluted in 1000ml of NaCl 0.9% and then infused using an infusion pump at corresponding speed. The placebo substance, made up of the vehicle alone, will also be intravenously administrated using the same procedure as that for the substance containing the active principle.

Patient's management Management of any underlying comorbidity will be at discretion of the attending physicians; the use of international guidelines for the monitoring and the adequate therapeutic interventions are recommended in all patients.

In particular, patients ventilation should be managed according to ATS/ESICM/SCCM 2017 consensus for the ventilation in ARDS patients which suggest low tidal volume ventilation (4-8 mL/Kg predicted body weight) associated with low plateau pressure (<30 cmH2O), high positive end-expiratory pressure (PEEP) associated with recruitment maneuvers and prone positioning for periods longer than 12h in severe ARDS patients. Arterial gas analysis assessment should be performed at maximum intervals of six hours or more often according to the attending physician beliefs. Maintenance fluid should be chosen among balanced crystalloids and the quantity will be decided by the attending physician. Glucose management, nutrition protocols, decision to administer neuromuscular blockade, prone positioning, ECMO, nitric oxide or any other adjunctive therapies will be continued according to center current clinical practice and will be recorded in the CRF file.

Weaning procedure Regarding the weaning from mechanical ventilation, in order to standardize and reduce bias we will comply with the following procedures based on ARDS Network protocol (ARDSnet).

Each day the patients enrolled will be assessed by the medical staff for the following weaning criteria:

  1. FiO2 ≤ 0.40 and PEEP ≤ 8 cmH2O OR FiO2 < 0.50 and PEEP < 5 cmH2O
  2. PEEP and FiO2 ≤ values of previous day.
  3. No neuromuscular blocking agents
  4. Patient has acceptable spontaneous breathing efforts (It will be allowed to decrease the respiratory rate on the ventilator up to 50% for 5 min to detect inspiratory effort)
  5. Systolic BP ≥ 90 mmHg

If all the above conditions will be met, medical staff will start a spontaneous breathing test (SBT) for up to 120 minutes using one of the following methods and maintaining a: FiO2 ≤ 0.5:

  1. T-piece Tube
  2. Pressure Support Ventilation ≤ 5 cmH2O with PEEP ≤ 5 cmH2O
  3. CPAP with PEEP ≤ 5 cmH2O
  4. Tracheal Collar mask

To test the tolerance at such measures the medical staff will evaluate the following goals for a minimum of 30 minutes up to 120 minutes:

  1. SpO2 ≥ 90% and / or PaO2 ≥ 60 mm Hg
  2. Mean spontaneous tidal volume ≥ 4 ml/kg PBW (if measured)
  3. Respiratory Rate ≤ 35 / min
  4. pH ≥ 7.30 (if measured)
  5. No respiratory distress (defined as 2 or more of the following):

    1. Heart rate ≥ 120% of the rate (≤ 5 min at > 120% may be tolerated)
    2. Marked use of accessory muscles
    3. Abdominal paradox
    4. Diaphoresis
    5. Marked subjective dyspnea

If all these goals will be met, the medical staff will consider extubation, otherwise the patient will be treated with the pre-weaning settings.

Data Collection Data collection on admission will include: demographic characteristics, comorbidities, including use of antihypertensive medications, source of admission, primary and secondary diagnosis, delay since symptoms begin, APACHE II Score (the worst values within the first 24 hours), SOFA score on admission, Chest X-ray and Thoracic CT scan results if available, EKG trace, PaO2/FiO2 on admission. Daily data collection during ICU stay will include: continuous hemodynamic monitoring, including invasive arterial pressure monitoring and continuous EKG; SaO2 and PaO2/FiO2 every 2 hours; blood samples including Hb, glucose and several other chemical variables will be collected at least once per day at 8 am (or the first value of the day); ventilatory parameters and arterial gas analysis will be also collected every six hours; SOFA score; presence of any other documented infection (site, pathogen, treatment); presence of septic shock; daily diuresis and daily total fluid infusion, urine analysis including main electrolytes (sodium, potassium, chloride, calcium) and osmolarity every morning. The occurrence of serious adverse events (see specific paragraph in the text). Duration of ICU stay, duration of mechanical ventilation, need for tracheostomy. In case of death, reasons for withdrawal of care will be recorded. All the data will be recorded using the specific CRF forms, divided into a core section and a daily section and will be uploaded to a web-centralized protected database.

Statistical Analysis

First phase (Phase IIb) = 15 vs 15 patients Second phase (Phase III) = expected 30 vs 30 patients in total (recalculation of sample size after 15 vs. 15 patients included)

The primary outcome of this study is the number of ventilator free days at day 28.

Considering an expected median duration of mechanical ventilation in COVID-19 related respiratory insufficiency patients of 14 days, to provide an absolute reduction of 22,5% with an alpha error of 0.05 and to provide a power to detect the effect of 80% and a dropout rate of 3%, 60 patients will need to be included in the primary analysis, 30 in each group.

Pre-planned Stratified group analysis will be performed for the following group of patients:

  1. History of hypertension vs. no history of hypertension
  2. Treatment with ACEi, ARB or DRI drugs vs no treatment
  3. Age (<65 vs. ≥ 65 years)
  4. PaO2/FiO2 values at randomization (<100 vs ≥ 100)
  5. Confirmed vs highly suspected COVID-19

Data Safety Management Members of the Data Safety Monitoring Committee (DSMC) are individuals free of conflicts of interest for this protocol; DSMC will analyze the safety of the study and their membership within the DSMC will be for the duration of this clinical trial. Serious Adverse Events (SAEs) will be recorded at the participating site on the specific CRF and their occurrence will be monitored by the DSMC at the different interim analysis. Formal meeting will be held for each interim analysis to review the data related to the primary outcome, the safety findings as well as the quality of the trial conduct. To enhance the integrity of the trial, the DSMC will have access to the different results aggregated by treatment group and remain unaware of the treatment assignment (the groups will be encoded as A and B). A report including data on recruitment and baseline characteristics and pooled data on eligibility violations will be prepared by the statistician for each DSMC meeting. Only the independent statistician will have access to the whole database. A closed report will be then prepared to allow confidential discussion of clinical data and the DSMC has to prepare minutes of their meetings, with a list of recommendations for the Steering Committee (to continue, to hold or to terminate the trial). If the recommendation is to stop the trial, a final decision will be made after the analysis of all patients included at the time (including patients randomized after data collection for the DSMC meeting). The Steering Committee will be responsible for deciding whether to continue, hold or stop the trial based on DSMC recommendations. The DSMC will be notified of all changes to the trial protocol or conduct.

Organization Data will be recorded using pre-printed CRF by the attending physician or a trained research nurse. All data will be periodically introduced by trained personnel in the central web-based database. The study coordinator will contact each time a patient is included the local PI to ensure data collection and reporting as well as completion of patient follow-up or on premature termination of the study protocol. The individual data provided by a participating ICU are primarily property of the ICU who generated the data. All investigators have the right to access their data every time.

The Principal Investigators of the study have the responsibility to perform periodic and spot checks visits to monitor the progress of the clinical study. Completed CRFs will be reviewed for completeness, compliance with investigation plan and appropriate device use and accountability. Case report forms will be uploaded on a website with the help of an independent statistician, which will be overseen data entry and data quality management. Data on safety will be provided to the DMSC with regular time intervals. The steering committee will review study integrity, safety and risk/benefit issues after 25 included patients. The rate of these reviews could increase according to report of relevant safety issues. Independent analyses of serious adverse events will be performed and adjudicated if the frequency or nature of serious adverse events warrants it.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Randomized, controlled, investigator initiated, phase II/phase III seamless, adaptive, single blinded, interventional trial to evaluate the efficacy, safety and clinical impact of intravenous Ang-(1-7) infusion compared to standard treatment in ICU patients with severe respiratory failure associated with COVID-19. This study will be conducted initially in one center (Erasme Hospital, Belgium), but other sites will be allowed to join if: Number of expected patients with COVID related ARF ≥ 10, experience in treatment of ARDS patients (> 25/year), including prone positioning ,availability of the equipment required to provide the blood sample processing and storage. We planned a first phase of the study where 30 patients will be randomly receiving Ang-(1-7) or placebo to confirm the safety. The Final power calculation will be reassessed after 30 included patients (i.e. 15 in each arm), in line with a preplanned expected total number of patients needed of 60.
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Randomization will be performed using sealed envelopes with a ratio of 1:1 including information on treatment assignment and a five-digit number, which will be open by the person responsible for drug constitution. Each vial or syringe will be then labeled with the randomly allocated number it will be assigned to the nursing personnel. The doctors and nurses administering the drugs, as well as the local investigators and research personnel who collected data, were unaware of the treatment assignments.
Primary Purpose: Treatment
Condition  ICMJE
  • Coronavirus
  • Respiratory Failure
  • Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere
  • SARS-CoV-2
Intervention  ICMJE
  • Drug: Angiotensin 1-7
    endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
  • Drug: Placebos
    infusion of NaCl 0.9% without diluted peptide in it
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Standard of care treatment
    Intervention: Drug: Placebos
  • Experimental: Study drug
    Angiotensin-(1-7) infusion (venous) of 0.2 mcg/Kg/h for 48h
    Intervention: Drug: Angiotensin 1-7
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: April 2, 2020)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 15, 2023
Estimated Primary Completion Date December 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age > 18 years old
  • Expected ICU stay of > 48 hours
  • Bilateral Viral Pneumonia
  • Orotracheal intubation from less than 24 hours
  • Confirmed or highly suspected COVID-19

Exclusion Criteria:

  • Patients with cancer (all stages) diagnosis
  • Severe hemodynamic instability (need of vasopressors >1 mcg/Kg/min to maintain a MAP > 65 mmHg)
  • Pregnant women
  • Immunocompromised patients
  • Limitations of care
  • Inclusion in any other interventional trial
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: filippo annoni, MD 0032(0)483141483 filippo.annoni@erasme.ulb.ac.be
Contact: Fabio S Taccone, PD,PhD fabio.tacconei@erasme.ulb.ac.be
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04332666
Other Study ID Numbers  ICMJE P2020/201
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Erasme University Hospital
Study Sponsor  ICMJE Erasme University Hospital
Collaborators  ICMJE Fonds Erasme pour la Recherche Médicale
Investigators  ICMJE
Principal Investigator: Filippo Annoni, MD Erasme hospital
Principal Investigator: Robson AS Santos, MD,PhD Minas Gerais University
PRS Account Erasme University Hospital
Verification Date August 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP